Valuation in Life Sciences [recurso electrónico] : A Practical Guide / by Boris Bogdan, Ralph Villiger.
Tipo de material: TextoEditor: Berlin, Heidelberg : Springer Berlin Heidelberg, 2010Descripción: XIV, 370 p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783642108204Tema(s): Economics | Biotechnology | Pharmacy | Medical records -- Data processing | Biology -- Data processing | Banks and banking | Industrial management | Economics/Management Science | Finance /Banking | Computer Appl. in Life Sciences | Health Informatics | Pharmacy | Biotechnology | Management/Business for ProfessionalsFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 657.8333 | 658.152 Clasificación LoC:HG1-9999HG4501-6051HG1501-HG3550Recursos en línea: Libro electrónicoTipo de ítem | Biblioteca actual | Colección | Signatura | Copia número | Estado | Fecha de vencimiento | Código de barras |
---|---|---|---|---|---|---|---|
Libro Electrónico | Biblioteca Electrónica | Colección de Libros Electrónicos | HG1 -9999 (Browse shelf(Abre debajo)) | 1 | No para préstamo | 373860-2001 |
Introduction -- The Life Sciences Industry -- Valuation -- Project Valuation -- License Contract Valuation -- Technology Valuation -- IP Valuation -- Firm Valuation -- Advanced Topics -- Valuation and Gut Feeling -- Excercises.
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including DCF, decision trees, and real options, the authors demonstrate how to value projects, patents, licences, firms, and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results. The 3rd edition of the successful work includes new studies about success rates and about drug development in the biotech industry and their influence on valuation.
19